Literature DB >> 12737318

Recombinant anti-P protein autoantibodies isolated from a human autoimmune library: reactivity, specificity and epitope recognition.

S Zampieri1, M Mahler, M Blüthner, Z Qiu, K Malmegrim, A Ghirardello, A Doria, W J van Venrooij, J M H Raats.   

Abstract

The ribosomal P proteins are specific and important autoantigens in patients affected by systemic lupus erythematosus. In this study, we describe for the first time the selection and characterization of recombinant human monoclonal anti-P protein (auto)-antibody fragments from an autoimmune patient-derived phage display antibody library. The selected recombinant anti-P antibodies specifically recognize the P proteins in immunofluorescence assays on HEp-2 cells and in immunoblotting assays, and they immunoprecipitate the P proteins under native conditions. Using both anti-P-positive patient sera and the selected recombinant anti-P antibodies, the immunodominant epitope was determined and shown to be located at the C-terminal end of the P proteins (amino acids 111-115). Inhibition of in vitro protein translation demonstrated that interaction of the monoclonal patient-derived anti-P antibodies with their native epitope functionally inhibits the activity of the P proteins on the ribosome, confirming the notion that patient autoantibodies are often directed to the functional centre of their autoantigenic target.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12737318     DOI: 10.1007/s000180300050

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  9 in total

1.  Characterization of anti-P monoclonal antibodies directed against the ribosomal protein-RNA complex antigen and produced using Murphy Roths large autoimmune-prone mice.

Authors:  H Sato; M Onozuka; A Hagiya; S Hoshino; I Narita; T Uchiumi
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

2.  Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins.

Authors:  M Mahler; K Kessenbrock; J Raats; R Williams; M J Fritzler; M Blüthner
Journal:  J Mol Med (Berl)       Date:  2003-03-14       Impact factor: 4.599

3.  The beta1 adrenergic effects of antibodies against the C-terminal end of the ribosomal P2beta protein of Trypanosoma cruzi associate with a specific pattern of epitope recognition.

Authors:  P Lopez Bergami; K A Gómez; G V Levy; V Grippo; A Baldi; M J Levin
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

4.  Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus.

Authors:  J L J Lin; V Dubljevic; M J Fritzler; Ban-Hock Toh
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 5.  Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review.

Authors:  M Zen; M Gatto; M Domeneghetti; L Palma; E Borella; L Iaccarino; L Punzi; A Doria
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

6.  Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection.

Authors:  K Kessenbrock; M J Fritzler; M Groves; P Eissfeller; C A von Mühlen; P Höpfl; M Mahler
Journal:  J Mol Med (Berl)       Date:  2007-08-01       Impact factor: 4.599

7.  Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies.

Authors:  Juan Irure-Ventura; Marcos López-Hoyos
Journal:  J Transl Autoimmun       Date:  2022-01-11

Review 8.  Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus?

Authors:  Emese Kiss; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

9.  Selective blockade of trypanosomatid protein synthesis by a recombinant antibody anti-Trypanosoma cruzi P2β protein.

Authors:  Maximiliano Juri Ayub; Benson Nyambega; Leandro Simonetti; Tomas Duffy; Silvia A Longhi; Karina A Gómez; Johan Hoebeke; Mariano J Levin; Cristian R Smulski
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.